TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE EUROPE SJS/TEN TREATMENT MARKET 84
1.4 LIMITATIONS 87
1.5 MARKETS COVERED 87
2 MARKET SEGMENTATION 92
2.1 MARKETS COVERED 92
2.2 GEOGRAPHICAL SCOPE 93
2.3 YEARS CONSIDERED FOR THE STUDY 94
2.4 CURRENCY AND PRICING 94
2.5 DBMR TRIPOD DATA VALIDATION MODEL 95
2.6 MULTIVARIATE MODELLING 98
2.7 TREATMENT LIFELINE CURVE 98
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 99
2.9 DBMR MARKET POSITION GRID 100
2.10 MARKET APPLICATION COVERAGE GRID 101
2.11 VENDOR SHARE ANALYSIS 102
2.12 SECONDARY SOURCES 103
2.13 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHTS 107
4.1 KEY TRENDS 108
4.2 COST OF TREATMENT 109
4.3 KEY PLAYERS STRATEGIES 110
4.4 LONG TERM GROWTH APPROACH 111
5 EPIDEMIOLOGY 112
6 INDUSTRY INSIGHTS 116
6.1 PATENT ANALYSIS 116
6.2 DEMOGRAPHIC TRENDS 118
6.3 PATIENT FLOW DIAGRAM 119
6.4 KEY PRICING STRATEGIES 120
6.5 KEY PATIENT ENROLLMENT STRATEGIES 120
7 MARKET OVERVIEW 123
7.1 DRIVERS 125
7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN 125
7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT 126
7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN 126
7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT 127
7.2 RESTRAINTS 129
7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN 129
7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT 129
7.3 OPPORTUNITIES 130
7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN 130
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT 131
7.4 CHALLENGES 131
7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN 131
7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT 132
8 EUROPE SJS/TEN TREATMENT MARKET, BY TREATMENT 133
8.1 OVERVIEW 134
8.2 MEDICATIONS 137
8.2.1 ANTIHISTAMINES 138
8.2.1.1 HYDROXYZINE 138
8.2.1.2 FEXOFENADINE 138
8.2.2 CORTICOSTEROID 139
8.2.2.1 DEXAMETHASONE 139
8.2.2.2 PREDNISOLONE 139
8.2.2.3 METHYLPREDNISOLONE 139
8.2.2.4 HYDROCORTISONE 139
8.2.2.5 OTHERS 139
8.2.3 ANTIBIOTICS 139
8.2.3.1 NAFCILLIN 140
8.2.3.2 GENTAMICIN 140
8.2.3.3 OTHERS 140
8.2.4 ANALGESICS 140
8.2.4.1 MORPHINE 140
8.2.4.2 FENTANYL CITRATE 141
8.2.4.3 OTHERS 141
8.2.5 ANTICOAGULANTS 141
8.2.6 ANTISEPTICS 141
8.2.6.1 CHLORHEXIDINE GLUCONATE 141
8.2.6.1.1 PERIOGARD 142
8.2.6.1.2 PERIDEX 142
8.2.6.1.3 AVAGARD 142
8.2.6.1.4 HIBICLENS 142
8.2.6.1.5 OTHERS 142
8.2.6.2 OCTENISEPT 142
8.2.6.3 POLYHEXANIDE SOLUTIONS 142
8.2.6.4 OTHERS 143
8.2.7 INTRAVENOUS IMMUNOGLOBULIN 143
8.2.8 CYCLOSPORINE 143
8.2.8.1 NEORAL 143
8.2.8.2 SANDIMMUNE 143
8.2.8.3 OTHERS 143
8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-)BLOCKING AGENT (ETANERCEPT) 143
8.2.10 OTHER TREATMENT 144
8.2.10.1 CYCLOPHOSPHAMIDE 144
8.2.10.2 N-ACETYLCYSTEINE 144
8.2.10.3 MONOCLONAL ANTIBODIES 144
8.2.10.4 THALIDOMIDE 144
8.3 SUPPORT CARE 144
8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES 145
8.3.2 PAIN MANAGEMENT 146
8.3.2.1 LIDOCAINE 146
8.3.2.2 OTHERS 146
8.3.3 NUTRITION SUPPORT 146
8.3.4 ORAL CARE 146
8.3.5 PLASMAPHERESIS 146
8.3.6 BANDAGES 146
8.3.6.1 BIOLOGICAL DRESSING 147
8.3.6.1.1 ALLOGRAFT 147
8.3.6.1.2 XENOGRAFT 147
8.3.6.1.3 HOMOGRAFT 147
8.3.6.1.4 OTHERS 147
8.3.6.2 BIOSYNTHETIC DRESSING 148
8.3.6.3 SILVER IMPREGNATED DRESSING 148
8.4 HOSPITALIZATION 148
8.5 ISOLATION 149
8.6 OINTMENTS 149
8.6.1 BENZOCAINE 150
8.6.2 AMERICAINE 150
8.6.3 ANBESOL 150
8.6.4 CHIGGEREX PLUS 150
8.6.5 OTHERS 151
8.7 OTHERS 151
9 EUROPE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS 152
9.1 OVERVIEW 153
9.2 PHYSICAL EXAM 156
9.3 SKIN BIOPSY 156
9.4 MEDICAL HISTORY 157
9.5 BLOOD TEST 158
9.5.1 COMPLETE BLOOD COUNT 159
9.5.2 ERYTHROCYTE SEDIMENTATION RATE 159
9.5.3 COAGULATION STUDIES 159
9.5.4 UREA AND ELECTROLYTES 160
9.5.5 LIVER FUNCTION TEST 160
9.6 CULTURES 160
9.7 OTHERS 161
10 EUROPE SJS/TEN TREATMENT MARKET, BY CAUSE 162
10.1 OVERVIEW 163
10.2 SPECIFIC TREATMENT 166
10.3 INFECTION 166
10.4 OTHERS 167
11 EUROPE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 168
11.1 OVERVIEW 169
11.2 ORAL 172
11.3 PARENTERAL 172
11.3.1 INTRAVENOUS 173
11.3.2 SUBCUTANEOUS 173
11.3.3 OTHERS 173
11.4 TOPICAL 173
11.4.1 OINTMENTS 174
11.4.2 SOLUTION 174
11.4.3 CREAMS 175
11.4.4 OTHERS 175
11.5 OTHERS 175
12 EUROPE SJS/TEN TREATMENT MARKET, BY DRUG TYPE 176
12.1 OVERVIEW 177
12.2 BRANDED 180
12.2.1 NEORAL 181
12.2.2 SANDIMMUNE 181
12.2.3 VISTARIL 181
12.2.4 DURAMORPH 181
12.2.5 FENTORA 181
12.2.6 ENBREL 181
12.2.7 OTHERS 181
12.3 GENERIC 181
13 EUROPE SJS/TEN TREATMENT MARKET, BY THERAPY TYPE 183
13.1 OVERVIEW 184
13.2 COMBINATION THERAPY 187
13.3 MONOTHERAPY 187
14 EUROPE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE 189
14.1 OVERVIEW 190
14.2 GERIATRIC 193
14.2.1 FEMALE 194
14.2.2 MALE 194
14.3 ADULT 194
14.3.1 FEMALE 195
14.3.2 MALE 195
14.4 PEDIATRIC 195
15 EUROPE SJS/TEN TREATMENT MARKET, BY END USER 197
15.1 OVERVIEW 198
15.2 HOSPITALS 201
15.3 SPECIALTY CLINICS 201
15.4 AMBULATORY SURGICAL CENTER 202
15.5 HOMECARE SETTING 203
15.6 OTHERS 203
16 EUROPE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL 205
16.1 OVERVIEW 206
16.2 RETAIL PHARMACIES 209
16.2.1 HOSPITAL ASSOCIATED PHARMACIES 210
16.2.2 DRUG STORE 210
16.2.3 ONLINE PHARMACIES 210
16.3 DIRECT TENDERS 210
16.4 OTHERS 211
17 EUROPE SJS/TEN TREATMENT MARKET, BY REGION 212
17.1 EUROPE 213
17.1.1 GERMANY 230
17.1.2 FRANCE 241
17.1.3 U.K. 252
17.1.4 ITALY 263
17.1.5 SPAIN 273
17.1.6 RUSSIA 283
17.1.7 TURKEY 294
17.1.8 BELGIUM 304
17.1.9 DENMARK 314
17.1.10 NETHERLANDS 325
17.1.11 SWITZERLAND 335
17.1.12 SWEDEN 345
17.1.13 POLAND 355
17.1.14 NORWAY 364
17.1.15 FINLAND 373
17.1.16 REST OF EUROPE 382
18 EUROPE SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE 383
18.1 COMPANY SHARE ANALYSIS: EUROPE 383
19 SWOT ANALYSIS 384
20 COMPANY PROFILE 385
20.1 PFIZER INC. 385
20.1.1 COMPANY SNAPSHOT 385
20.1.2 REVENUE ANALYSIS 385
20.1.3 COMPANY SHARE ANALYSIS 386
20.1.4 PRODUCT PORTFOLIO 386
20.1.5 RECENT DEVELOPMENT 386
20.2 NOVARTIS AG 387
20.2.1 COMPANY SNAPSHOT 387
20.2.2 REVENUE ANALYSIS 387
20.2.3 COMPANY SHARE ANALYSIS 388
20.2.4 PRODUCT PORTFOLIO 388
20.2.5 RECENT DEVELOPMENT 388
20.3 MERCK & CO., INC. 389
20.3.1 COMPANY SNAPSHOT 389
20.3.2 REVENUE ANALYSIS 389
20.3.3 COMPANY SHARE ANALYSIS 390
20.3.4 PRODUCT PORTFOLIO 390
20.3.5 RECENT DEVELOPMENT 390
20.4 AMNEAL PHARMACEUTICAL LLC. 391
20.4.1 COMPANY SNAPSHOT 391
20.4.2 REVENUE ANALYSIS 391
20.4.3 COMPANY SHARE ANALYSIS 392
20.4.4 PRODUCT PORTFOLIO 392
20.4.5 RECENT DEVELOPMENT 392
20.5 AMGEN INC. 393
20.5.1 COMPANY SNAPSHOT 393
20.5.2 REVENUE ANALYSIS 393
20.5.3 PRODUCT PORTFOLIO 394
20.5.4 RECENT DEVELOPMENT 394
20.6 ADVACARE PHARMA 395
20.6.1 COMPANY SNAPSHOT 395
20.6.2 PRODUCT PORTFOLIO 395
20.6.3 RECENT DEVELOPMENT 395
20.7 BD 396
20.7.1 COMPANY SNAPSHOT 396
20.7.2 REVENUE ANALYSIS 396
20.7.3 PRODUCT PORTFOLIO 397
20.7.4 RECENT DEVELOPMENT 397
20.8 CARDINAL HEALTH 398
20.8.1 COMPANY SNAPSHOT 398
20.8.2 REVENUE ANALYSIS 398
20.8.3 PRODUCT PORTFOLIO 399
20.8.4 RECENT DEVELOPMENT 399

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.